Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Byrd, John; Hillmen, Peter; Ghia, Paolo; Kater, Arnon; Chanan-Khan, Asher; Furman, Richard; O'Brien, Susan; YENEREL, MUSTAFA; Illes, Arpad; Kay, Neil; Garcia-Marco, Jose; Mato, Anthony; Pinilla-Ibarz, Javier; Seymour, John; Lepretre, Stephane; Stilgenbauer, Stephan; Robak, Tadeusz; Rothbaum, Wayne; Izumi, Raquel; Hamdy, Ahmed; Patel, Priti; Higgins, Kara; Sohoni, Sophia; Jurczak, Wojciech

doi:10.1200/jco.21.01210

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Byrd J. C., Hillmen P., Ghia P., Kater A. P., Chanan-Khan A., Furman R. R., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.31, ss.3441-3454, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 31
Basım Tarihi: 2021
Doi Numarası: 10.1200/jco.21.01210
Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.3441-3454
İstanbul Üniversitesi Adresli: Evet

Özet

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).